Jump to content

FDA lifts hold on Telik cancer drug trials


Recommended Posts

Silicon Valley / San Jose Business Journal

Telik Inc. said Monday a partial hold on clinical trials for its cancer drug was lifted by the U.S. Food and Drug Administration.

The Palo Alto-based biopharm (NASDAQ:TELK) said it was asked in June to temporarily halt trials for Telcyta, designed to treat ovarian and lung cancer.

The company said the FDA had some safety concerns over the drug.

Telik said that after a complete review of data, regulators permitted clinical development to resume on Telcyta.

Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Reply to this topic...

×   Pasted as rich text.   Restore formatting

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

  • Create New...

Important Information

By using this site, you agree to our Terms of Use.